SuperworthNiagen Bioscience EV/EBIT NAGE
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2025.
- Today, Oct 23, 2026
- 14.9×
- Peer median
- 17.1×
Niagen Bioscience's EV/EBIT is 14.9× as of Oct 23, 2026.
The median for 4 chemicals stocks of a similar size is 17.1×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 14.9× | 14.9× | 24.2× |
| 2025 | 24.3× | 23.5× | 80.7× |
Against its peers
Companies in Chemicals nearest Niagen Bioscience's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| NAGENiagen Bioscience | 14.9× |
| FTLFFitlife Brands | n/m |
| FTKFlotek Industries | 23.7× |
| BTMDbiote | 10.5× |
| CRONCronos | n/m |
| Peer median | 17.1× |
Where Niagen Bioscience ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Niagen Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.